Search

everythinglearnresearchcommunity

for

Search:↓

User experienced hair regrowth using Min, Fin, RU, micro needling, and keto. Others encouraged consistency and shared excitement for future progress.

OP is considering mixing finasteride pills with a 60ml bottle of Redensyl to create a topical treatment. The discussion focuses on the feasibility and effectiveness of this approach for hair loss.

Hair loss discussion mentions treatments Minoxidil, Finasteride, and RU58841. Verteporfin shows promise for scar/regrowth after 84 days.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

A user shared impressive hair regrowth results after 4 months using topical minoxidil, oral finasteride, and 3 PRP sessions. They plan to continue with these treatments and add dermastamping.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The user experienced no improvement in hair loss with finasteride and minoxidil but had side effects. They plan to add wounding, scalp massage, vitamin K, and taurine supplements to their regimen and seek feedback on these additions.

The conversation is about purchasing RU58841 for hair loss treatment from Xian Lyphar BioTech. Users confirm the company is legitimate and the price is reasonable.

The user is using finasteride for hair loss and is frustrated with shedding but plans to add oral minoxidil for convenience and safety. There are concerns about using topical minoxidil around pets.

GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

Hair loss treatments, specifically experiences with Redensyl as well as other treatments such as Minoxidil, finasteride and RU58841.

A user shared their positive experience with hair regrowth using 1mg finasteride and 5% topical minoxidil daily, showing significant improvement in hair density over six months. The conversation includes supportive comments and questions about the treatment details, such as whether finasteride was taken orally or topically and if microneedling was used.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

The conversation is about the delay in the release of GT20029 phase 2 results by Kintor. It also mentions Minoxidil, finasteride, and RU58841 as treatments for hair loss.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

The user "OP" uses a combination of topical minoxidil 5%, finasteride 0.025%, and caffeine to combat hair loss, with noticeable results over 5-6 months. Side effects include unwanted body hair growth and an itchy scalp, but no significant sexual side effects.

The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

A user inquired about Hair XL offered by a clinic in the Netherlands, questioning if it is a form of Exosome treatment. The conversation seeks experiences and clarity on the treatment.

Hair regrowth using 0.9% KX-826 every morning and 5% Minoxidil every night. Results are not expected in 45 days; more time is needed.

The user experienced high liver enzyme levels, possibly due to topical finasteride or supplements, and decided to stop using finasteride while continuing minoxidil. After stopping finasteride and supplements, liver levels returned to normal, suggesting finasteride or supplements might have been the cause.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

This conversation was about a user's experience with hair loss treatments over two years, using finasteride and minoxidil which resulted in significant improvement.

User used topical minoxidil 5% with 0.1% finasteride twice daily, oral minoxidil 2.5mg, and finasteride 1mg daily, along with a hair multivitamin and weekly derma rolling. They missed the medication 3-4 times but still saw significant progress.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The conversation discusses whether a product recommended by a Portuguese pharmacist is the same as Minoxidil. Treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

Hair loss discussion includes fluridil (eucapil) and alfatradiol. Users share improvement experiences and alternative treatments in comments.